IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

NCT05805956 | Unknown Phase 1 DMC FDA Drug

• 1 other identifier: IMM2902-001
• Study Type: interventional
• Target: 105
• Locations: 1 country
• Sites: 2

Brief Summary

This trial is an open-label, multicenter, first-in-human dose-escalation and cohort expansion Phase I/II clinical study to evaluate the safety, tolerability and preliminary efficacy of IMM2902 in the treatment of HER2-expressing advanced solid tumors

Conditions

Advanced Solid Tumor; Advanced Lung Cancer; Advanced Gastric Carcinoma; Advanced Cholangiocarcinoma

Outcome Measures

Primary Outcomes (7)

• maximum tolerated dose (MTD) of IMM2902

  Observe the safety and tolerability of IMM2902 in patients with advanced solid tumors expressing human epidermal growth factor receptor 2 (HER2), so as to determine the MTD

  48 weeks

• recommended phase 2 dose (RP2D) of IMM2902

  Observe the safety and tolerability of IMM2902 in patients with advanced solid tumors expressing human epidermal growth factor receptor 2 (HER2), so as to determine the RP2D

  48 weeks

• Treatment-related adverse events as assessed by CTCAE v5.0

  To evaluate the safety of IMM2902

  48 weeks

• objective response rate

  proportion of subjects whose tumors achieved CR and PR after treatment

  48 weeks

• disease control rate

  the proportion of subjects whose tumors achieved CR, PR and SD after treatment

  48 weeks

• duration of response

  the time from the beginning of recording an objective response to the first occurrence of tumor progression, or death from any cause

  48 weeks

• progression-free survival

  the time from the start of treatment to tumor progression or death from any cause

  48 weeks

Study Arms (1)

IMM2902

EXPERIMENTAL

Phase 1 is the dose escalation part, patients with HER2 expressing solid tumors will be enrolled in groups of different dose levels, to explore MTD, RP2D, safety, and preliminary efficacy of IMM2902. Phase 2 is the cohort expansion part, patients with HER2 overexpressing advanced solid tumors will be enrolled in three cohorts, to explore the safety and efficacy of IMM2902.

Drug: IMM2902

Interventions

IMM2902 DRUG

a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47

IMM2902

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntarily sign the Informed Consent Form (ICF) and follow the protocol requirements;
• Age ≥ 18 years old and ≤ 75 years old, regardless of gender;
• Expected survival time ≥ 12 weeks;
• HER2 expression:
• HER2 protein expression or HER2 gene amplification was found in primary or metastatic tumor tissue (IHC) or FISH.
• Phase I (dose escalation phase):
• HER2 expression is defined as IHC1+, IHC2+ or IHC3+, FISH testing is not required, and testing results from local qualified medical institutions are acceptable.
• Phase II (cohort expansion phase):
• HER2 overexpression is defined as IHC 3+ or IHC 2+, which can be tested by local qualified medical institutions.
• Clinical diagnosis:
• Phase I (dose escalation phase):
• Patients with advanced solid tumors with HER2 expression (IHC1+, IHC2+ or IHC3+) confirmed by histology or cytology, who have previously received standard treatment progress, treatment ineffective or no standard treatment plan, including but not limited to breast cancer, gastric cancer (including gastroesophageal combination adenocarcinoma), urothelial carcinoma, biliary tract carcinoma, ovarian cancer, colon cancer and non-small cell lung cancer.
• Phase II (cohort expansion phase), including 3 cohorts:
• Cohort 1: Histologically or cytologically confirmed unresectable locally advanced or metastatic non-small cell lung cancer with HER2 overexpression (IHC3+ or IHC2+), who have previously failed systemic therapy; Cohort 2: Unresectable locally advanced or metastatic gastric cancer (including gastroesophageal junction adenocarcinoma) with histologically or cytologically confirmed HER2 overexpression (IHC3+ or IHC2+), who have previously received at least two systemic regimens.
• Cohort 3: Unresectable locally advanced or metastatic biliary tract cancer with histologically or cytologically confirmed HER2 overexpression (IHC3+ or IHC2+), recurrence or disease progression after previous standard treatment.

You may not qualify if:

• Received the last systemic or local anti-tumor therapy within 4 weeks before the first administration, including chemotherapy, immunotherapy, biological agents, etc.; received hormone anti-tumor therapy, small molecule targeted therapy within 2 weeks before the first administration; Palliative local treatment for non-target lesions within 2 weeks before the first administration; received non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, tumor necrosis factor, etc., not including IL-11 for the treatment of thrombocytopenia); Chinese herbal medicine or Chinese patent medicine with anti-tumor indications within 1 week before the first administration.
• Received therapeutic drugs targeting SIRPα/CD47 4 weeks before the first administration, such as CD47 antibody, SIRPα fusion protein, SIRPα antibody and SIRPγ fusion protein;
• Patients with primary central nervous system (CNS) malignant tumors or active CNS metastases who have failed local treatment (radiotherapy or surgery), but the following patients are allowed to enroll: a. Asymptomatic brain metastases; b. Clinical symptoms are stable (that is, there is no imaging progress 4 weeks before the first administration, and any neurological symptoms have returned to the baseline level), and corticosteroids and other treatments for brain metastases are not required for ≥4 weeks;
• Uncontrolled hypertension (systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg) or pulmonary hypertension or unstable angina pectoris; myocardial infarction or bypass or stent surgery within 6 months before administration; Chronic heart failure history of grade III-IV of NYHA criteria; clinically significant valvular disease; serious arrhythmia requiring treatment (except atrial fibrillation, paroxysmal supraventricular tachycardia), including male QTc ≥ 450ms, Female QTc≥470ms (calculated by Fridericia formula); cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 12 months before enrollment;
• History of arterial thrombosis, deep vein thrombosis and pulmonary embolism within 3 months before the first administration;
• Have a history of moderate or severe dyspnea at rest due to advanced malignant tumors or their complications or severe primary lung diseases, or currently require continuous oxygen therapy, or currently suffer from interstitial lung disease (ILD), severe chronic obstructive pulmonary disease, severe pulmonary insufficiency, symptomatic bronchospasm, etc.;
• Suffering from other malignant tumors within 5 years before the first administration. Except: a. Cervical carcinoma in situ or non-melanoma skin cancer that has been radically cured; b. Second primary cancer that has been radically cured and has no recurrence within five years; c. The investigators believe that both primary cancers can benefit from this study;
• Diseases that may cause gastrointestinal bleeding or perforation (such as duodenal ulcer, intestinal obstruction, acute Crohn's disease, ulcerative colitis, large-scale gastric and small intestinal resection, etc.); patients with chronic Crohn's disease and patients with ulcerative colitis (except those with total colon and rectal resection), even in the inactive phase, should be excluded; those with hereditary nonpolyposis colorectal cancer or familial adenomatous polyposis syndrome; Perforation, intestinal fistula history, but not cured after surgical treatment; esophageal and gastric varices;
• Need puncture and drainage to treat uncontrollable pleural, abdominal and pericardial effusions that require repeated drainage or have obvious symptoms;
• Have active hepatitis B \[hepatitis B virus surface antigen (HBsAg) positive and/or hepatitis B virus antibody (HBcAb) positive, and HBV DNA ≥ 2000 IU/ml, and hepatitis caused by drugs or other reasons is excluded\], or active hepatitis C \[anti-hepatitis C virus (HCV) antibody positive, and HCV RNA is higher than the lower limit of detection, and hepatitis caused by drugs or other causes is excluded\];
• Has a history of immunodeficiency, including human immunodeficiency virus (HIV) infection, or other immunodeficiency diseases, or has a history of organ transplantation;
• Have a history of autoimmune diseases, including but not limited to systemic lupus erythematosus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, Hashimoto's thyroiditis, autoimmune thyroid disease, multiple sclerosis, etc. patient. except:
• Hypothyroidism that can be controlled only by hormone replacement therapy;
• Skin diseases that do not require systemic treatment (such as vitiligo, and psoriasis);
• Controlled celiac disease. However, patients who are using immunosuppressants or systemic hormone therapy (prednisone or other equivalent hormones at a dose ≥ 10 mg/day) and continue to use them within 2 weeks before enrollment cannot be enrolled;

Sponsors & Collaborators

• ImmuneOnco Biopharmaceuticals (Shanghai) Inc.: lead

Study Sites (2)

301 Hospital

Beijing, China

RECRUITING

Fudan University Cancer Hospital

Shanghai, China

RECRUITING

Central Study Contacts

Dinglu Chen

CONTACT

18616907141; dinglu.chen@immuneonco.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 23, 2023
• First Posted: April 10, 2023
• Study Start: February 15, 2022
• Primary Completion: October 1, 2024
• Study Completion: October 1, 2024
• Last Updated: April 10, 2023

Record last verified: 2023-03

Locations

CN (2)